<DOC>
	<DOCNO>NCT02290522</DOCNO>
	<brief_summary>Patients advance solid tumor refer Phase 1 Unit offer map GA identification pt could benefit personalized treatment .</brief_summary>
	<brief_title>Copenhagen Prospective Personalized Oncology ( CoPPO )</brief_title>
	<detailed_description>Two ultrasound-guided biopsy obtain store RNAlaterÂ® DNA RNA purification . A 3rd biopsy histology paraffin embed . SNP-array ( Affymetrix Cytoscan HD ) DNA ( tumor ) perform identify copy number change . Whole exome sequencing ( WES ) DNA ( tumor blood ) perform use sequence capture , SureSelect v5 ( Agilent ) Illumina HiSeq2500 call tumor specific mutation . Expression level therapeutic target reveal expression Array tumor RNA . In addition expression array , RNA-seq ( Nugens Ovation RNA-seq system v2 ) perform investigate whether chromosomal translocation reason tumor specific expression oncogene . Results review tumor board . Patients specific genetic profile target market drug drug development offer treatment . PFS treatment compare PFS recent standard treatment ( PFS ratio ) .</detailed_description>
	<criteria>Solid tumor No standard treatment option PS 01 Lesion assessable biopsy Measurable disease Informed consent Life expectancy &lt; 3 month Bone marrow suppression Abnormal renal hepatic function Serious concurrent medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>